Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
Cancer Immunology, Immunotherapy, April 22, 2013
Lode HN et al. - Immunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric malignancy characterized by poor outcome. The authors report the induction of a GD2-specific immune response with ganglidiomab, a new anti-idiotype antibody to anti-GD2 antibodies of the 14.18 family. They generated and characterized a novel anti-idiotype antibody ganglidiomab and demonstrated activity against neuroblastoma.
Basic study and Phase I clinic trial of anti-idiotypic antibody mimicking nasopharyngeal carcinoma cell antigen
Chinese Journal of Cancer Research, June 3, 2013
Xie L et al. - An anti-idiotypic monoclonal antibody 2A9 (Ab2) was prepared, which mimicked the nasopharynegeal carcinoma (NPC) cell antigen defined by anti-NPC McAb Fcl. The results showed that 2A9 was safe in applying on NPC patients and induced some humoral and/or cellular immune responses.
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--The Mimosa Study
Journal of Clinical Oncology, March 15, 2013
Sabbatini P et al. - Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response. Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS. Methods Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of ...